Welcome to our dedicated page for Abcellera Biologics SEC filings (Ticker: ABCL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AbCellera Biologics Inc. (Nasdaq: ABCL) SEC filings page on Stock Titan provides structured access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. AbCellera is a clinical-stage biotechnology company focused on antibody-based medicines in endocrinology, women’s health, immunology, and oncology, and its filings offer detailed insight into its financial position, partnered programs, and clinical-stage activities.
Here you can review AbCellera’s current and periodic reports, including Form 8-K filings that disclose material events. Recent 8-Ks have covered topics such as quarterly financial and operational results, the appointment of a Chief Medical Officer, changes to the Board of Directors, and a settlement and patent license agreement with Bruker Corporation that resolved patent litigation globally and provides for upfront and royalty payments. These documents help explain how AbCellera manages leadership transitions, intellectual property matters, and communication of key business milestones.
AbCellera’s filings also identify it as a British Columbia–organized issuer with shares listed on Nasdaq under Commission File Number 001-39781, and they provide definitions of key business metrics such as partner-initiated program starts with downstream participation and molecules in the clinic. Investors can use annual reports on Form 10-K and quarterly reports on Form 10-Q, when available, to analyze revenue from research fees, licensing, and milestone payments, as well as research and development, sales and marketing, and general and administrative expenses.
Stock Titan enhances these SEC documents with AI-powered summaries that highlight important sections, explain technical language, and point out items that may matter to shareholders, such as liquidity, deferred revenue, and deferred government contributions. Users can also monitor Form 4 and related insider transaction reports, along with proxy statements, to better understand executive and director changes and compensation structures. With real-time updates from EDGAR and AI-generated insights, this ABCL filings page helps readers navigate complex regulatory disclosures more efficiently.
AbCellera Biologics Inc. (ABCL) furnished a press release and investor presentation related to its financial and operational results for the quarter ended September 30, 2025. The company aligned the materials with its earnings call on November 6, 2025, and provided them as exhibits.
The information under Items 2.02 and 7.01 is being furnished, not filed, and is not subject to Section 18 liability nor incorporated by reference except as stated. Exhibits include 99.1 (press release) and 99.2 (corporate presentation).
AbCellera Biologics Inc. filed a report describing a leadership change in its medical organization. Sarah Noonberg, M.D., Ph.D., has been appointed as the company’s Chief Medical Officer, a key role overseeing medical strategy and clinical development. The company announced this appointment in a press release dated September 10, 2025, which is included as an exhibit to the report.
The filing classifies this as an "Other Event" and does not include financial results or transaction details. It confirms that AbCellera’s common shares trade on The Nasdaq Stock Market LLC under the symbol ABCL and that the report was signed by Chief Executive Officer Carl L. G. Hansen.